Fiche du document
- doi: 10.1111/ene.14368
- issn: 1351-5101
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1111/ene.14368
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/32478936
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1468-1331
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_A149616B606F8
info:eu-repo/semantics/openAccess , All rights reserved , https://serval.unil.ch/disclaimer
Sujets proches
Therapy Infectious diseasesCiter ce document
A.M. Lascano et al., « SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome. », Serveur académique Lausannois, ID : 10.1111/ene.14368
Métriques
Partage / Export
Résumé
The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system. From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2. These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance. We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.